TY - JOUR
T1 - Successful management of malignant hyperpyrexia syndrome in a pediatric patient
T2 - What to do when dantrolene is not available?
AU - Gupta, Priyanka
AU - Kamal, Geeta
AU - Gupta, Mayank
N1 - Publisher Copyright:
© 2015 Journal of Pharmacology and Pharmacotherapeutics | Published by Wolters Kluwer - Medknow.
Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Malignant hyperpyrexia syndrome (MHS) is a rare entity and may not be encountered by the anaesthesiologists throughout their professional career. Whenever it manifests can be a challenging task to manage and prove to be fatal when a timely diagnosis and required therapeutic measures are not taken. Althoughthe dantrolene should be available wherever anaesthesia is practiced, considering the rarity of the syndrome this may not be the scenario always. We are reporting a case of MHS in a pediatric patient to highlight the facts that prompt clinical diagnosis, ongoing supportive treatment, discontinuation of all the anaesthetic agents and and stringent perioperative monitoring along with postoperative oral dantrolene may provide an answer to the MHS crisis in the face of an unavailability of the IV dantrolene; as may be the case in many rural and developing set-ups.
AB - Malignant hyperpyrexia syndrome (MHS) is a rare entity and may not be encountered by the anaesthesiologists throughout their professional career. Whenever it manifests can be a challenging task to manage and prove to be fatal when a timely diagnosis and required therapeutic measures are not taken. Althoughthe dantrolene should be available wherever anaesthesia is practiced, considering the rarity of the syndrome this may not be the scenario always. We are reporting a case of MHS in a pediatric patient to highlight the facts that prompt clinical diagnosis, ongoing supportive treatment, discontinuation of all the anaesthetic agents and and stringent perioperative monitoring along with postoperative oral dantrolene may provide an answer to the MHS crisis in the face of an unavailability of the IV dantrolene; as may be the case in many rural and developing set-ups.
UR - http://www.scopus.com/inward/record.url?scp=84952769092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952769092&partnerID=8YFLogxK
U2 - 10.4103/0976-500X.171873
DO - 10.4103/0976-500X.171873
M3 - Article
AN - SCOPUS:84952769092
SN - 0976-500X
VL - 6
SP - 211
EP - 213
JO - Journal of Pharmacology and Pharmacotherapeutics
JF - Journal of Pharmacology and Pharmacotherapeutics
IS - 4
ER -